Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Siah E3 ubiquitin protein ligase 1 pseudogene 1 (**SIAH1P1**) is classified in the human genome as a pseudogene, meaning it is a non-functional copy of the SIAH1 gene that has accumulated sequence changes resulting in the loss of protein-coding potential[2]. Pseudogenes like SIAH1P1 may be transcribed in some tissues but do not produce functional proteins. While pseudogenes in general can participate in regulatory roles such as acting as competing endogenous RNAs, there is no published evidence assigning a regulatory or disease-related function to SIAH1P1 itself[4]. The gene is sometimes referred to by its alias "SIAH1L." It is not considered a drug target nor is it associated with disease biomarker status. Note: If you are seeking information about the functional E3 ubiquitin ligase "Siah E3 ubiquitin protein ligase 1" (SIAH1), that would be a different entity and is a bona fide enzyme with roles in ubiquitination and cell signaling, whereas SIAH1P1 is a pseudogene and not utilized as a therapeutic target[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Siah E3 ubiquitin protein ligase 1 pseudogene 1 (SIAH1P1).